Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IFOSFAMIDE Cause Malignant neoplasm progression? 671 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 671 reports of Malignant neoplasm progression have been filed in association with IFOSFAMIDE (IFEX). This represents 4.0% of all adverse event reports for IFOSFAMIDE.

671
Reports of Malignant neoplasm progression with IFOSFAMIDE
4.0%
of all IFOSFAMIDE reports
210
Deaths
120
Hospitalizations

How Dangerous Is Malignant neoplasm progression From IFOSFAMIDE?

Of the 671 reports, 210 (31.3%) resulted in death, 120 (17.9%) required hospitalization, and 43 (6.4%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IFOSFAMIDE. However, 671 reports have been filed with the FAERS database.

What Other Side Effects Does IFOSFAMIDE Cause?

Off label use (2,281) Febrile neutropenia (2,225) Disease progression (1,912) Neutropenia (1,509) Drug ineffective (1,331) Thrombocytopenia (1,227) Anaemia (1,067) Product use in unapproved indication (890) Pyrexia (752) Sepsis (712)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which IFOSFAMIDE Alternatives Have Lower Malignant neoplasm progression Risk?

IFOSFAMIDE vs IGURATIMOD IFOSFAMIDE vs ILOPERIDONE IFOSFAMIDE vs ILOPROST IFOSFAMIDE vs IMATINIB IFOSFAMIDE vs IMBRUVICA

Related Pages

IFOSFAMIDE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression IFOSFAMIDE Demographics